Breadcrumb

Douglas K. Price, Ph.D.

Douglas K. Price, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - Magnuson CC, Room 5A01
  • Bethesda, MD 20892
  • 240-858-3206
  • 240-858-3020
  • dkprice@mail.nih.gov

RESEARCH SUMMARY

Dr. Price’s research focuses on the molecular biology of prostate cancer with emphasis on the goals of (1) understanding the biology of prostate cancer progression and the transition from androgen-dependent disease to castrate resistant prostate cancer (CRPC), (2) exploring the impact of genetic polymorphisms in androgen regulatory pathways on clinical outcomes, and (3) developing targeted therapies against CRPC with emphasis on the design and development of small molecule inhibitors of angiogenesis, transporters and hypoxia factors. Dr. Price also acts as the laboratory biorepository curator, overseeing the banking and storage of genetic materials from patients with prostate cancer.

Areas of Expertise

1) molecular biology, 2) genetics, 3) prostate cancer, 4) angiogenesis

Publications

Selected Publications

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results from the Prostate Cancer Prevention Trial

Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Tonggon C, Varella-Garcia M, Reichardt JKV, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS
Urology. 84: 127-31, 2014. [ Journal Article ]

Epidithiodiketopiperazines (ETPs) exhibit antiangiogenic and antitumor activity by disrupting the HIF-1alpha/p300 complex in a preclinical model of prostate cancer

Reece KM, Richardson ED, Cook KM, Campbell TJ, Pisle ST, Holley AJ, Venzon DJ, Liewehr DJ, Chau CH, Price DK, Figg WD
Mol Cancer . 13: 91, 2014. [ Journal Article ]

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial

Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BE, Minasian L, Parnes H, Tangen CM, Kristal AR, Thompson IM, Figg WD
J Urol . 184: 2297-2302, 2010. [ Journal Article ]

A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer

Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, Gulley JL, Price DK, Dahut WL, Figg WD
BJU Int. 102: 617-21, 2008. [ Journal Article ]

Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostate cancer

Hamada A, Sissung TM, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao CK, Sparreboom A, Mitsuya H, Dahut WL, Figg WD
Clin Cancer Res. 14: 3312-8, 2008. [ Journal Article ]